CRIS Cancer Foundation
C/ Princesa de Éboli, nº 9, Madrid, 28050, Spain
Overview
Cris Against Cancer is a non-profit organization that offers research, prevention treatments, and outback programs to defeat cancer.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Health Care
- Hospital
- Non Profit
Investment portfolio
- Infinitopes
Participated · Seed · May 2024
Infinitopes combines AI-driven antigen discovery with high-efficiency viral vectors to build a scalable, off-the-shelf cancer vaccine platform. Its lead program, ITOP1, targets prevention of recurrence in oesophageal cancer and is entering a first-in-human, placebo-controlled Phase I/IIa study (VISTA) across multiple UK NHS university cancer centres. Supported by Cancer Research UK and embedded in Oxford University’s BioEscalator, the company has grown from three academic founders to roughly 20 full-time employees. Non-dilutive backing includes two maximum-size Innovate UK awards and an Innovative Licensing and Access Pathway passport from the MHRA. Beyond ITOP1, Infinitopes plans to expand its precision vaccine approach to additional solid tumours. To date the company has secured more than $35.1 million in equity financing from sector-focused investors such as Octopus Ventures, Amplify Bio, Cancer Research Horizons, Manta Ray Ventures and others. The fresh capital will fund the VISTA trial and further platform development.
Team
No current team members are available.